---
document_datetime: 2025-12-17 15:05:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tasigna.html
document_name: tasigna.html
version: success
processing_time: 0.1257741
conversion_datetime: 2026-01-03 13:21:29.435906
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tasigna

[RSS](/en/individual-human-medicine.xml/66656)

##### Authorised

This medicine is authorised for use in the European Union

nilotinib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tasigna](#news-on)
- [More information on Tasigna](#more-information-on-tasigna-747)
- [More information on Tasigna](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tasigna is a medicine for treating chronic myelogenous leukaemia (CML) - a blood cancer - in patients who have been newly diagnosed or who cannot take other cancer medicines (including imatinib) because they cause side effects or do not work for them.

Tasigna is only for patients with a special chromosome in their cancer cells called the Philadelphia chromosome. Tasigna is used during the chronic phase of the cancer in adults and children, when the condition is developing slowly and the patient has few or no symptoms. It can also be used in adults during the accelerated phase (when the cancer cells are dividing rapidly and the patient may have more symptoms).

CML is rare, and Tasigna was designated an 'orphan medicine' (a medicine used in rare diseases) on 22 May 2006.

Tasigna contains the active substance nilotinib.

Expand section

Collapse section

## How is Tasigna used?

The medicine is available as capsules to be taken twice a day on an empty stomach. For patients who are unable to swallow capsules the content of the capsules can be mixed in a teaspoon of apple puree and swallowed.

The dose of Tasigna depends on the age of the patient and whether they have previously had treatment for CML, as well as the phase of the disease. Treatment can continue for as long as the patient benefits from it. Adults whose CML is well controlled may stop treatment but should have regular tests to check that the disease has not started to come back. For more information about using Tasigna, see the package leaflet or contact your doctor or pharmacist.

Tasigna can only be obtained with a prescription and treatment should be started by a doctor who has experience in the diagnosis and treatment of CML.

## How does Tasigna work?

The active substance in Tasigna, nilotinib, belongs to a group of medicines called 'protein kinase inhibitors'. Nilotinib acts by blocking the protein kinase called Bcr-Abl kinase which is produced by leukaemia cells that have the Philadelphia chromosome, and causes them to multiply uncontrollably. By blocking Bcr-Abl kinase, Tasigna helps to control the spread of leukaemia cells.

## What benefits of Tasigna have been shown in studies?

A number of studies have shown that Tasigna has important effects which can help keep CML under control. Below is a brief description of the studies and what effects they measured:

- A study in 320 adults with chronic phase CML showed that treatment with Tasigna can lead to what is known as a major cytogenetic response (when the proportion of white blood cells in the bone marrow containing the Philadelphia chromosome falls to below 35%). In this study around 49% of patients, most of whom had stopped responding to imatinib, achieved this response after around 11 months on Tasigna treatment.
- Another study in 119 adults with accelerated phase CML looked at the haematological response (when the number of white cells in the blood returns to normal). This response was achieved in 42% of patients, most of whom had also stopped responding to imatinib, after around seven months of Tasigna treatment.
- A third study in 846 newly diagnosed adults with chronic phase CML compared Tasigna with imatinib. It focused on another measure called a major molecular response (when the proportion of the patient's white blood cells that can produce the abnormal Bcr-Abl kinase falls to below 0.1%). Depending on the dose, between 43% and 44% of patients taking Tasigna achieved this response after 12 months compared with 22% of patients taking imatinib.
- Two further studies in adults with chronic phase CML who were treated with Tasigna for at least 3 years and whose disease was well controlled for at least a year showed that the medicine's benefits can be maintained after stopping treatment. In one of the studies in 190 patients initially treated with Tasigna, 52% maintained a response after 48 weeks of stopping Tasigna. In the second study in 126 patients who had been switched from imatinib to Tasigna, 58% maintained their response 48 weeks after stopping Tasigna.
- Finally, a study showed that Tasigna was also effective in children with CML in the chronic phase. In this study of 58 children, a major molecular response was achieved with Tasigna at 6 months in 39% of children whose cancer did not respond to other medicines such as imatinib, and 64% of those with newly diagnosed cancer by 12 months.

## What are the risks associated with Tasigna?

The most common side effects with Tasigna (which may affect more than 1 in 10 people) are thrombocytopenia (low blood platelet counts), neutropenia (low white blood cell counts), headache, nausea (feeling sick), rash, pruritus (itching), myalgia (muscle pain), upper abdominal (belly) pain, tiredness, hair loss and high blood levels of liver and pancreatic enzymes and bilirubin For the full list of side effects and restrictions with Tasigna, see the package leaflet.

## Why is Tasigna approved?

Tasigna has been shown to improve the condition of patients with CML by reduction of the number of cancer cells with the Philadelphia chromosome and return of white blood cell levels to normal. The side effects of the medicine are considered to be manageable. The European Medicines Agency therefore decided that Tasigna's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tasigna?

The company that markets Tasigna will provide further data on the benefits in children from an ongoing study.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tasigna have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tasigna are continuously monitored. Side effects reported with Tasigna are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tasigna

Tasigna received a marketing authorisation valid throughout the EU on 19 November 2007.

Tasigna : EPAR - Summary for the public

English (EN) (221.23 KB - PDF)

**First published:** 02/06/2009

**Last updated:** 06/05/2019

[View](/en/documents/overview/tasigna-epar-summary-public_en.pdf)

Tasigna : EPAR - Risk Management Plan

English (EN) (809.59 KB - PDF)

**First published:** 11/05/2023

[View](/en/documents/rmp/tasigna-epar-risk-management-plan_en.pdf)

## Product information

Tasigna : EPAR - Product Information

English (EN) (781.53 KB - PDF)

**First published:** 29/09/2009

**Last updated:** 17/12/2025

[View](/en/documents/product-information/tasigna-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-128)

български (BG) (954.97 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/bg/documents/product-information/tasigna-epar-product-information_bg.pdf)

español (ES) (890.47 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/es/documents/product-information/tasigna-epar-product-information_es.pdf)

čeština (CS) (860.67 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/cs/documents/product-information/tasigna-epar-product-information_cs.pdf)

dansk (DA) (756.47 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/da/documents/product-information/tasigna-epar-product-information_da.pdf)

Deutsch (DE) (889.41 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/de/documents/product-information/tasigna-epar-product-information_de.pdf)

eesti keel (ET) (786.3 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/et/documents/product-information/tasigna-epar-product-information_et.pdf)

ελληνικά (EL) (973.23 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/el/documents/product-information/tasigna-epar-product-information_el.pdf)

français (FR) (847.77 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/fr/documents/product-information/tasigna-epar-product-information_fr.pdf)

hrvatski (HR) (846.71 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/hr/documents/product-information/tasigna-epar-product-information_hr.pdf)

íslenska (IS) (812.13 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/is/documents/product-information/tasigna-epar-product-information_is.pdf)

italiano (IT) (855.18 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/it/documents/product-information/tasigna-epar-product-information_it.pdf)

latviešu valoda (LV) (889.96 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/lv/documents/product-information/tasigna-epar-product-information_lv.pdf)

lietuvių kalba (LT) (879.44 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/lt/documents/product-information/tasigna-epar-product-information_lt.pdf)

magyar (HU) (931.43 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/hu/documents/product-information/tasigna-epar-product-information_hu.pdf)

Malti (MT) (1.12 MB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/mt/documents/product-information/tasigna-epar-product-information_mt.pdf)

Nederlands (NL) (784.12 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/nl/documents/product-information/tasigna-epar-product-information_nl.pdf)

norsk (NO) (833.28 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/no/documents/product-information/tasigna-epar-product-information_no.pdf)

polski (PL) (882.35 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/pl/documents/product-information/tasigna-epar-product-information_pl.pdf)

português (PT) (923.84 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/pt/documents/product-information/tasigna-epar-product-information_pt.pdf)

română (RO) (933.6 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/ro/documents/product-information/tasigna-epar-product-information_ro.pdf)

slovenčina (SK) (955.26 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/sk/documents/product-information/tasigna-epar-product-information_sk.pdf)

slovenščina (SL) (885.77 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/sl/documents/product-information/tasigna-epar-product-information_sl.pdf)

Suomi (FI) (738.03 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/fi/documents/product-information/tasigna-epar-product-information_fi.pdf)

svenska (SV) (793.39 KB - PDF)

**First published:**

29/09/2009

**Last updated:**

17/12/2025

[View](/sv/documents/product-information/tasigna-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000318973 17/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tasigna : EPAR - All Authorised presentations

English (EN) (90.54 KB - PDF)

**First published:** 29/11/2007

**Last updated:** 17/05/2021

[View](/en/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-962)

български (BG) (103.87 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/bg/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_bg.pdf)

español (ES) (91.12 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/es/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_es.pdf)

čeština (CS) (95.52 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/cs/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (93.64 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/da/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (92.61 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/de/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (90.09 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/et/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (98.03 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/el/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_el.pdf)

français (FR) (92.11 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/fr/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (92.73 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/hr/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (92.39 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/is/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_is.pdf)

italiano (IT) (92.59 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/it/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (95.67 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/lv/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (97.39 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/lt/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (98.5 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/hu/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (98.67 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/mt/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (89.86 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/nl/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (92.66 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/no/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_no.pdf)

polski (PL) (95.6 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/pl/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_pl.pdf)

português (PT) (91.14 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/pt/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_pt.pdf)

română (RO) (93.93 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/ro/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (96.85 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/sk/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (93.08 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/sl/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (89.73 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/fi/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (92.64 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

17/05/2021

[View](/sv/documents/all-authorised-presentations/tasigna-epar-all-authorised-presentations_sv.pdf)

Tasigna : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (15.82 KB - PDF)

**First published:** 29/11/2007

**Last updated:** 29/11/2007

[View](/en/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (21)](#file-language-dropdown-738)

български (BG) (93.9 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/bg/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (16.46 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/es/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (94.14 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/cs/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (16.4 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/da/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (16.68 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/de/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (16.86 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/et/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (86.66 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/el/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (16.61 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/fr/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

italiano (IT) (16.3 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/it/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (95.37 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/lv/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (97.08 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/lt/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (90.3 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/hu/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (96.05 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/mt/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (16.4 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/nl/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

polski (PL) (97.43 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/pl/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (16.35 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/pt/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (92.46 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/ro/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (93.72 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/sk/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (86.41 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/sl/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (16.37 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/fi/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (16.46 KB - PDF)

**First published:**

29/11/2007

**Last updated:**

29/11/2007

[View](/sv/documents/conditions-member-states/tasigna-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Tasigna Active substance nilotinib International non-proprietary name (INN) or common name nilotinib Therapeutic area (MeSH) Leukemia, Myelogenous, Chronic, BCR-ABL Positive Anatomical therapeutic chemical (ATC) code L01EA03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Tasigna is indicated for the treatment of:

- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,
- paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib.

Tasigna is indicated for the treatment of:

- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,
- adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available,
- paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.

## Authorisation details

EMA product number EMEA/H/C/000798 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 19/11/2007 Revision 48

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tasigna : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (145.99 KB - PDF)

**First published:** 17/12/2025

[View](/en/documents/procedural-steps-after/tasigna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tasigna : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (358.73 KB - PDF)

**First published:** 08/10/2009

**Last updated:** 17/12/2025

[View](/en/documents/procedural-steps-after/tasigna-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tasigna-H-C-000798-P46-056 : EPAR - Assessment report

Adopted

Reference Number: EMA/167947/2024

English (EN) (2.48 MB - PDF)

**First published:** 15/05/2024

[View](/en/documents/variation-report/tasigna-h-c-000798-p46-056-epar-assessment-report_en.pdf)

Tasigna-H-C-000798-P46-055 : EPAR - Assessment Report

Adopted

Reference Number: EMA/700721/2022

English (EN) (700.83 KB - PDF)

**First published:** 26/10/2022

[View](/en/documents/variation-report/tasigna-h-c-000798-p46-055-epar-assessment-report_en.pdf)

Tasigna-H-C-PSUSA-00002162-202001 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/37441/2021

English (EN) (129.46 KB - PDF)

**First published:** 22/01/2021

[View](/en/documents/scientific-conclusion/tasigna-h-c-psusa-00002162-202001-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Tasigna-H-C-798-P46-054 : EPAR - Assessment Report

Adopted

Reference Number: EMA/520858/2019

English (EN) (659.05 KB - PDF)

**First published:** 24/01/2020

[View](/en/documents/variation-report/tasigna-h-c-798-p46-054-epar-assessment-report_en.pdf)

Tasigna-H-C-PSUSA-00002162-201901 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/691903/2019

English (EN) (129.68 KB - PDF)

**First published:** 07/01/2020

[View](/en/documents/scientific-conclusion/tasigna-h-c-psusa-00002162-201901-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Tasigna-H-C-798-X-0088-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/54558/2018

English (EN) (5.01 MB - PDF)

**First published:** 16/04/2018

**Last updated:** 16/04/2018

[View](/en/documents/variation-report/tasigna-h-c-798-x-0088-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tasigna

Reference Number: EMA/CHMP/595185/2017

English (EN) (118.65 KB - PDF)

**First published:** 15/09/2017

**Last updated:** 15/09/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tasigna_en.pdf)

Tasigna-H-C-798-II-0084-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/313746/2017

English (EN) (2.09 MB - PDF)

**First published:** 19/07/2017

**Last updated:** 19/07/2017

[View](/en/documents/variation-report/tasigna-h-c-798-ii-0084-g-epar-assessment-report-variation_en.pdf)

Tasigna : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/207552/2016

English (EN) (3.1 MB - PDF)

**First published:** 18/03/2016

**Last updated:** 18/03/2016

[View](/en/documents/variation-report/tasigna-epar-assessment-report-variation_en.pdf)

Tasigna-H-C-798-X-0028 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/CHMP/678208/2010

English (EN) (633.3 KB - PDF)

**First published:** 17/01/2011

**Last updated:** 17/01/2011

[View](/en/documents/variation-report/tasigna-h-c-798-x-0028-epar-assessment-report-extension_en.pdf)

Tasigna-H-C-798-II-0029 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/678167/2010

English (EN) (613.31 KB - PDF)

**First published:** 17/01/2011

**Last updated:** 17/01/2011

[View](/en/documents/variation-report/tasigna-h-c-798-ii-0029-epar-assessment-report-variation_en.pdf)

CHMP summary of positive opinion for Tasigna

Adopted

Reference Number: EMA/CHMP/462567/2010

English (EN) (55.65 KB - PDF)

**First published:** 24/09/2010

**Last updated:** 24/09/2010

[View](/en/documents/smop/chmp-summary-positive-opinion-tasigna_en.pdf)

## Initial marketing authorisation documents

Tasigna : EPAR - Procedural steps taken before authorisation

English (EN) (22.53 KB - PDF)

**First published:** 29/11/2007

**Last updated:** 29/11/2007

[View](/en/documents/procedural-steps/tasigna-epar-procedural-steps-taken-authorisation_en.pdf)

Tasigna : EPAR - Scientific Discussion

English (EN) (415.32 KB - PDF)

**First published:** 29/11/2007

**Last updated:** 29/11/2007

[View](/en/documents/scientific-discussion/tasigna-epar-scientific-discussion_en.pdf)

#### News on Tasigna

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2017) 15/09/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 June 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-june-2014) 27/06/2014

#### More information on Tasigna

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-06-375) on 22 May 2006. Tasigna was withdrawn from the Community register of orphan medicinal products in November 2019 at the end of the 12-year period of market exclusivity.

#### More information on Tasigna

- [EMEA-000290-PIP01-08-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000290-pip01-08-m04)
- [Tasigna - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/tasigna)
- [A PROSPECTIVE NON-INTERVENTIONAL SAFETY STUDY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA RECEIVING NILOTINIB IN DAILY PRACTICE ACCORDING TO UPDATED GUIDELINES - post-authorisation study](https://catalogues.ema.europa.eu/study/16550)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/12/2025

## Share this page

[Back to top](#main-content)